David Groeger1, Elisa Schiavi2, Ray Grant3, Magdalena Kurnik-Łucka4, David Michalovich5, Rick Williamson5, Soren Beinke5, Barry Kiely6, Cezmi A Akdis7, Edith M Hessel5, Fergus Shanahan8, Liam O' Mahony8. 1. Alimentary Health Pharma Davos, Davos, Switzerland; PrecisionBiotics Group Ltd., Cork, Ireland; Lead contact. Electronic address: dgroeger@precisionbiotics.com. 2. Alimentary Health Pharma Davos, Davos, Switzerland; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland. 3. Alimentary Health Pharma Davos, Davos, Switzerland. 4. Department of Pathophysiology, Jagiellonian University Medical College, Krakow, Poland. 5. GSK, Stevenage, United Kingdom. 6. PrecisionBiotics Group Ltd., Cork, Ireland. 7. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland. 8. Department of Medicine and School of Microbiology, APC Microbiome Ireland, National University of Ireland, Cork, Ireland.
Abstract
BACKGROUND: Prophylactic strategies are urgently needed for prevention of severe inflammatory responses to respiratory viral infections. Bacterial-host interactions may modify the immune response to viral infections. METHODS: We examined the contribution of Intranasal administration of two different Bifidobacterium longum strains or its isolated cell wall in controlling viral induced inflammation using a murine model of influenza infection. We monitored mortality and morbidity over a 10-day period and viral load, differential broncho alveolar lavage (BAL) fluid inflammatory cell counts, Lung tissue histology, BAL and serum cytokines, markers of vascular damage and cell death were quantified. FINDINGS: Intranasal administration of Bifidobacterium longum35624® or its isolated cell wall prior to virus inoculation significantly reduced viral load within the lungs and significantly improved survival. Reduced viral load was associated with reduced lung injury as suggested by cell death and vascular leakage markers, a shift from neutrophil to macrophage recruitment, reduced inflammatory cytokine levels (including IL-6), reduced type 1 and 2 interferon levels, but increased levels of interferon-λ and surfactant protein D. These protective effects were maintained when the bifidobacterial cell wall preparation was administered 24 h after viral inoculation. The protective effects were also observed for the Bifidobacterium longumPB-VIR™ strain. INTERPRETATION: Exposure to these bifidobacterial strains protect against the inflammatory sequelae and damage associated with uncontrolled viral replication within the lung. FUNDING: This work has been funded, in part, by a research grant from GlaxoSmithKline, PrecisionBiotics Group Ltd., Swiss National Science Foundation grants (project numbers CRSII3_154488, 310030_144219, 310030_127356 and 310030_144219) and Christine Kühne - Center for Allergy Research and Education (CK-CARE).
BACKGROUND: Prophylactic strategies are urgently needed for prevention of severe inflammatory responses to respiratory viral infections. Bacterial-host interactions may modify the immune response to viral infections. METHODS: We examined the contribution of Intranasal administration of two different Bifidobacterium longum strains or its isolated cell wall in controlling viral induced inflammation using a murine model of influenza infection. We monitored mortality and morbidity over a 10-day period and viral load, differential broncho alveolar lavage (BAL) fluid inflammatory cell counts, Lung tissue histology, BAL and serum cytokines, markers of vascular damage and cell death were quantified. FINDINGS: Intranasal administration of Bifidobacterium longum35624® or its isolated cell wall prior to virus inoculation significantly reduced viral load within the lungs and significantly improved survival. Reduced viral load was associated with reduced lung injury as suggested by cell death and vascular leakage markers, a shift from neutrophil to macrophage recruitment, reduced inflammatory cytokine levels (including IL-6), reduced type 1 and 2 interferon levels, but increased levels of interferon-λ and surfactant protein D. These protective effects were maintained when the bifidobacterial cell wall preparation was administered 24 h after viral inoculation. The protective effects were also observed for the Bifidobacterium longumPB-VIR™ strain. INTERPRETATION: Exposure to these bifidobacterial strains protect against the inflammatory sequelae and damage associated with uncontrolled viral replication within the lung. FUNDING: This work has been funded, in part, by a research grant from GlaxoSmithKline, PrecisionBiotics Group Ltd., Swiss National Science Foundation grants (project numbers CRSII3_154488, 310030_144219, 310030_127356 and 310030_144219) and Christine Kühne - Center for Allergy Research and Education (CK-CARE).
Authors: Patrycja Konieczna; David Groeger; Mario Ziegler; Remo Frei; Ruth Ferstl; Fergus Shanahan; Eamonn M M Quigley; Barry Kiely; Cezmi A Akdis; Liam O'Mahony Journal: Gut Date: 2011-11-03 Impact factor: 23.059
Authors: David Groeger; Liam O'Mahony; Eileen F Murphy; John F Bourke; Timothy G Dinan; Barry Kiely; Fergus Shanahan; Eamonn M M Quigley Journal: Gut Microbes Date: 2013-06-21
Authors: Krist Helen Antunes; Gisele Cassão; Leonardo Duarte Santos; Sofia Giacomet Borges; Juliana Poppe; João Budelon Gonçalves; Eduarda da Silva Nunes; Guilherme Fernando Recacho; Vitória Barbosa Sousa; Gabriela Souza Da Silva; Daniel Mansur; Renato T Stein; Christian Pasquali; Ana Paula Duarte De Souza Journal: Front Immunol Date: 2022-05-05 Impact factor: 8.786
Authors: Margherita Tiezzi; Sofia Morra; Jimmy Seminerio; Alain Van Muylem; Audrey Godefroid; Noémie Law-Weng-Sam; Anne Van Praet; Véronique Corbière; Carmen Orte Cano; Sina Karimi; Véronique Del Marmol; Benjamin Bondue; Mariam Benjelloun; Philomène Lavis; Françoise Mascart; Philippe van de Borne; Alessandra K Cardozo Journal: Front Med (Lausanne) Date: 2022-02-08
Authors: Fabiana Olimpio; José Roberto Mateus da Silva; Rodolfo P Vieira; Carlos R Oliveira; Flavio Aimbire Journal: Clinics (Sao Paulo) Date: 2022-03-15 Impact factor: 2.365
Authors: Sabine Hazan; Neil Stollman; Huseyin S Bozkurt; Sonya Dave; Andreas J Papoutsis; Jordan Daniels; Brad D Barrows; Eamonn Mm Quigley; Thomas J Borody Journal: BMJ Open Gastroenterol Date: 2022-04